Physiopathology of Sodium Retention in Acromegaly (AcromEnaC)
|Study Design:||Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Physiopathology of Sodium Retention in Acromegaly|
- To compare natriuretic effect of a single dose administration of amiloride (20 mg) in patients with acromegaly [ Time Frame: before and after treatment of acromegaly. ]
- To compare natriuretic effect of a single dose of furosemide (bolus 5 mg, then 10 mg over 2 hrs) in patients with acromegaly [ Time Frame: before and after treatment of acromegaly. ]
- To study the difference of the intranasal potential [ Time Frame: before and after treatment of acromegaly. ]
|Study Start Date:||September 2007|
|Study Completion Date:||December 2009|
|Primary Completion Date:||December 2009 (Final data collection date for primary outcome measure)|
To compare natriuretic effect of a single dose administration of amiloride (20 mg) in patients with acromegaly
To prove this, we compared the response to amiloride administrated before and after treatment of acromegaly in the same subject. We will also compare the response to furosemide administrated before and after treatment of acromegaly in the same subject. We expected that the response to amiloride will be greater before than after treatment, while the response to furosemide will be lesser before than after treatment.
Definition: Extended description of the protocol, including information not already contained in other fields, such as comparison(s) studied.
Patients will be recruited in the Department of Endocrinology and Reproductive diseases in BICETRE University Hospital and will be explored in the Centre for Clinical Investigation of HEGP. Investigations will be performed during 4 separate day-hospital stays (2 pre-treatment and 2 post treatment) in the CIC of HEGP. The tests will consist of blood and urine sample collections before and after a single dose administration of furosemide or amiloride. The tests will be performed before treatment of acromegaly in random order and separated by 48hours, interval performed before treatment, and repeated in the same order after normalization of IGF1 by appropriate treatment.
The study will last for 2 years, with a 12 months maximal participation of each patient
Please refer to this study by its ClinicalTrials.gov identifier: NCT00531908
|Paris, France, 75000|
|Principal Investigator:||Peter KAMENICKY, MD||Assistance Publique - Hôpitaux de Paris|